Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-Study

Autoimmunity Reviews

Volumn 5, Issue 4, 2006, Pages 269-272

  Manger, Karin ^a   Wildt, Ludwig ^b   Kalden, Joachim R ^a   Manger, Bernhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cyclophosphamide; GnRH analogue; PREGO Study; Premature ovarian failure; SLE

Indexed keywords

CYCLOPHOSPHAMIDE; FOLLITROPIN; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; DRUG DERIVATIVE; FERTILITY PROMOTING AGENT; GONADORELIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AMENORRHEA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMALE FERTILITY; GONAD FUNCTION; GONADAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; PROSPECTIVE STUDY;

ADULT; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; OVARIAN FAILURE, PREMATURE; PROSPECTIVE STUDIES;

EID: 33746910250     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2005.10.001     Document Type: Review

References (16)

1. Manger K., Manger B., Repp R., Geisselbrecht M., Geiger A., Pfahlberg A., et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61 (2002) 1065-1070
2. Manger K., Kusus M., Foster C., Ropers D., Daniel W., Kalden J., et al. Factors associated with coronary artery calcification in young female SLE patients. Ann Rheum Dis 62 (2003)
3. Wallace W.H., Shalet S.M., Tetlow L.J., and Morris-Jones P.H. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 21 (1993) 333-339
4. Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., and Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11 (1996) 1620-1626
5. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 (1996) 1718-1729
6. Chapman R.M. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 9 (1982) 84-94
7. Kreuser E.D., Felsenberg D., Behles C., Seibt-Jung H., Mielcarek M., Diehl V., et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 4 (1992) 105-110
8. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 187 (2002) 93-105
9. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig 8 (2001) S60-S64
10. Blumenfeld Z., Avivi I., Ritter M., and Rowe J.M. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 6 (1999) 229-239
11. Blumenfeld Z., Shapiro D., Shteinberg M., Avivi I., and Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9 (2000) 401-405
12. Ataya K.M., McKanna J.A., Weintraub A.M., Clark M.R., and LeMaire W.J. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45 (1985) 3651-3656
13. Glode L.M., Robinson J., and Gould S.F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1 (1981) 1132-1134
14. Blumenfeld Z. Treatment with gonadotropin-releasing hormone agonists and prevention of multiple gestations in lupus or antiphospholipid syndrome patients undergoing in vitro fertilization: comment on the article by Guballa et al. Arthritis Rheum 46 (2002) 2542 [discussion 2542]
15. Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better?. Fertil Steril 76 (2001) 443-444
16. Blumenfeld Z., and Ritter M. Inhibin, activin, and follistatin in human fetal pituitary and gonadal physiology. Ann NY Acad Sci 943 (2001) 34-48